Pharmacotherapy in patients with idiopathic pulmonary fibrosis

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 11, 2008, Pages 1909-1925

  Nagai, S ^a   Handa, T ^b   Kim, D S ^c  

^a Central Clinic in Kyoto   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Asan Medecal Center   (South Korea)

Author keywords

Antifibrotic drugs; Corticosteroids; Idiopathic pulmonary fibrosis; Immunomodulatory drugs; Immunosuppressive drugs; Pulmonary hypertension; Usual interstitial pneumonia

Indexed keywords

ACETYLCYSTEINE; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; AZATHIOPRINE; BOSENTAN; COLCHICINE; CONNECTIVE TISSUE GROWTH FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; ENDOTHELIN RECEPTOR ANTAGONIST; FG 3019; GAMMA INTERFERON; IMATINIB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; OXYGEN; PENICILLAMINE; PHOSPHODIESTERASE V INHIBITOR; PIRFENIDONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR A; PREDNISOLONE; PREDNISONE; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASODILATOR AGENT; WARFARIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BONE MARROW TOXICITY; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; DOPPLER ECHOCARDIOGRAPHY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; HUMAN; HYPOXEMIA; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MALAISE; MONOTHERAPY; MORTALITY; MYALGIA; NONHUMAN; PATHOGENESIS; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SMOKING CESSATION; SURVIVAL RATE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; PULMONARY FIBROSIS;

EID: 49649098812     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.11.1909     Document Type: Review

References (124)

1. Idiopathic Pulmonary Fibrosis. Diagnosis and Treatment International Consensus Statement. The Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2):646-64
2. American Throacic Society/European Respiratory Society. American Thoracic Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respirat Crit Care Med 2002;165:277-304
3. King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopatbalogic features and mortality. Am J Respir Crit Care Med 2001;164(6):1025-32
4. Selman M, King TE Jr, Pardo A. About its pathogenesis and implications to therapy. Ann Intern Med 2001;134:136-51
5. Nagao T, Nagai S, Kitaichi M, et al. Are histological changes found in parallel with the progression of IPF/UIP? Am J Respir Crit Care Med 1998;167:A69
6. Nicholson AG, Colby TV, Du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J. Respir Crit Care Med 2000;162(6):2213-7
7. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164(9):1722-7
8. Kim DS, Nagai S. Idiopathic nonspecific interstitial pneumonia An unrecognized autoimmune disease? Am J Respir Crit Care Med 2007;176:632-3
9. Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006;39(3):233-41
10. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respirat Crit Care Med 2007;176(7):691-7
11. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3(4):285-92
12. Nagai S, Nagao T, Kitaichi M, Izumi T. Clinical courses of asymptomatic cases with idiopathic pulmonary fibrosis and a histology of usual interstitial pneumonia. Eur Respir J 1998;11:131s
13. Nagai S, Kitaichi M, Hamada K, et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidosis Vasc Diffuse Lung Dis 1999;16(2):209-14
14. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment Am J Med 1990;88(4):396-404
15. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998;113(2):396-400
16. Nicod LP. Recognition and treatment of idiopathic pulmonary fibrosis. Drugs 1998;55(4):555-62
17. Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3(4):330-8
18. Nathan SD. Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach. Clin Chest Med 2006;27(1 Suppl 1):S27-35
19. Davies HR, Richeldi L. Idiopathic pulmonary fibrosis: current and future treatment options. Am J Respir Med 2002;1(3):211-24
20. Daniels CE, Ryu JH. Treatment of idiopathic pulmonary fibrosis. Semin Respirat Crit Care Med 2006;27(6):668-76
21. Lynch III JP, Saggar R, Weigt SS, et al. Usual interstitial pneumonia. Semin Respir Crit Care Med 2006;27(6):634-51
22. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 1996;110(4):1058-67
23. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980;35(8):593-9
24. Tukiainen P, Taskinen E, Holsti P, et al. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983;38(5):349-55
25. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998;157(4 Part 1):1063-72
26. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003;58(2):143-8
27. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respirat Crit Care Med 2007;175(7):705-11
28. Rudd RM, Prescott RJ, Chalmers JC, Johnston ID; Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2007;62(1):62-6
29. Agustí, Xaubet A, Agustí AG, et al. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. Eur Respirat J 1994;7(4):643-50
30. Pujols L, Xaubet A, Ramírez J, et al. Expression of glucocorticoid receptors alpha and beta in steroid sensitive and steroid insensitive interstitial lung diseases. Thorax 2004;59(8):687-93
31. Flaherty KR, Toews GB, Lynch JP III, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001;110(4):278-82
32. Shah NR, Noble P, Jackson RM, et al. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22(3):167-74
33. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003;(3):CD002880
34. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144(2):291-6
35. Pereira CA, Malheiros T, Coletta EM, et al. Survival in idiopathic pulmonary fibrosis - cytotoxic agents compared to corticosteroids. Respir Med 2006;100(2):340-7
36. Kondoh Y, Taniguchi H, Yokoi T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005;25(3):528-33
37. Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004;125(6):2169-74
38. Zisman DA, Lynch III JP, Toews GB, et al. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000;117(6):1619-26
39. Van Oortegem K, Wallaert B, Marquette CH, et al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 1994;7(11):1950-7
40. Kolb M, Kirschner J, Riedel W, et al. Cyclophosphamide pulse therapy irs idiopathic pulmonary fibrosis. Eur Respir J 1998;12(6):1409-14
41. Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992;102(4):1090-4
42. Inase N, Sawada M, Ohtani Y, et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med 2003;42(7):565-70
43. Homma S, Sakamoto S, Kawabata M, et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005;44:1144-50
44. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003;(3):CD003134
45. Rennard SI, Bitterman PB, Ozaki T, et al. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro The basis of a possible therapeutic approach of the fibrotic disorders. Am Rev Respir Dis 1988;137:181-5
46. Addrizzo-Harris DJ, Harkin TJ, Tchou-Wong KM, et al. Mechanisms of colchicine effect in the treatment of asbestosis and idiopathic pulmonary fibrosis. Lung 2002;180:61-72
47. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Cell Mol Biol 1998;158:220-5
48. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Cell Mol Biol 2000;161:1172-8
49. Selman M, Carrillo G, Salas J, et al. D-Penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998;114:507-12
50. Eickelberg O, Pansky A, Koehler E, et al. Molecular mechanisms of tgf-(beta) antagonism by interferon (gamma) and cyclosporine a in lung fibroblasts. FASEB J 2001;15:797-806
51. Narayanan AS, Whithey J, Souza A, Raghu G. Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992;101:1326-31
52. Antoniou KM, Alexandrakis MG, Sfiridaki K, et al. Th1 cytokine pattern (il-12 and il-18) in bronchoalveolar lavage fluid (balf) before and after treatment with interferon gamma-1b (ifn-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (ipf/uip). Sarcoidosis Vasc Diffuse Lung Dis 2004;21:105-10
53. Kahan A, Amor B, Menkes CJ, Strauch G. Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 1989;87:273-7
54. Saez-Royuela F, Porres JC, Moreno A, et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis c: a randomized, controlled trial. Hepatology (Baltimore MD) 1991;13:327-31
55. Kalra S, Utz JP, Ryu JH. Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin Proc 2003;78:1082-7
56. Prasse A, Muller KM, Kurz C, et al. Does interferon-gamma improve pulmonary function in idiopathic pulmonary fibrosis? Eur Respirat J 2003;22:906-11
57. Nathan SD, Barnett SD, Moran B, et al. Interferon gamma-1b as therapy for idiopathic pulmonary fibrosis. An intrapatient analysis. Respiration 2004;71:77-82
58. Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9
59. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33
60. Hill AR. Interferon gamma-1b for pulmonary fibrosis. N Engl J Med 2004;350:1794-7; author reply 1794-7
61. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-7
62. Bajwa EK, Ayas NT, Schulzer M, et al. Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest 2005;128:203-6
63. Antoniou KM, Nicholson AG, Dimadi M, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 2006;28:496-504
64. Honore I, Nunes H, Groussard O, et al. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;167:953-7
65. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;291:367-73
66. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Cell Mol Biol 1999;159:1061-9
67. Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002;41:1118-23
68. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respirat Crit Care Med 2005;171:1040-7
69. Mathai SC, Polito AJ. The questionable efficacy of pirfenidone in ipf. Am J Respir Crit Care Med 2005;172:1228
70. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respirat Dis 1989;139:370-2
71. Behr J, Degenkolb B, Maier K, et al. Increased oxidation of extracellular glutathione by bronchoalveolar inflammatory cells in diffuse fibrosing alveolitis. Eur Respir J 1995;8:1286-92
72. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Cell Mol Biol 1997;156:1897-901
73. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteune in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42
74. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-82
75. Kinder BW, Collard HR, King TE Jr. Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest 2006;130:302-3
76. Cooper JA Jr. Pulmonary fibrosis: pathways are slowly coming into light. Am J Respir Cell Mol Biol 2000;22:520-3
77. Sime PJ, O'Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001;99:308-19
78. Available from: http://www.clinicaltrials.gov
79. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-316
80. Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 2003;14:91-8
81. Antoniades HN, Bravo MA, Avila RE, et al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990;86:1055-64
82. Homma S, Nagaoka I, Abe H, et al. Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Cell Mol Biol 1995;152:2084-9
83. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6
84. Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005;171:1279-85
85. Vuorinen K, Gao F, Oury TD, et al. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 2007;33:357-73
86. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16
87. Rajda J, Phatak PD. Reversible drug-induced interstitial pneumonitis following imatunib mesylate therapy. Am J Hematol 2005;79:80-1
88. Seki N, Ito A, Watanabe K, et al. Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med 2007;46:1941-2
89. Takigawa M. CTGF/Hcs24 as a multifunctional growth factor for fibroblasts, chondrocytes and vascular endothelial cells. Drug News Perspect 2003;16:11-21
90. Mageto Y, Flaherty K, Brown K, et al. Safety and tolerability of human monoclonal antibody fg-3019, anti-connective tissue growth factor, in patients with idiopathic pulmonary fibrosis. Chest 2004;126:773S
91. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007;131:650-6
92. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005;128:2393-9
93. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with interstitial pneumonias: comparison between idiopathic and collagen vascular disease associated interstitial pneumonias. Intern Med 2007;46:831-7
94. Whelan TP, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005;24:1269-74
95. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respirat Cell Mol Biol 2004;170:360-5
96. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respirat Cell Mol Biol 1999;160(2):600-7
97. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900
98. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;13l:897-9
99. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Cell Mol Biol 2003;168:1084-90
100. Hallstrand TS, Boitano LJ, Johnson WC, et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103
101. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respirat Cell Mol Biol 2006;174:803-9
102. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Am J Respir Cell Mol Biol 2000;161:487-92
103. Handa T, Nagai S, Kawabata D, et al. Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med 2005;44:319-25
104. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65
105. Sasayama S, Kunieda T, Tomoike H, et al. Effects of the endothelin receptor antagonist Bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J 2005;69:131-7. Erratum in: Circ J 2005;69:1007
106. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist Bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23
107. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. Erratum in: N Engl J Med 2002;346:1258
108. Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:417-25
109. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respirat Cell Mol Biol 1997;156:600-8
110. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993;341:1550-4
111. Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-93
112. Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of Bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81
113. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43
114. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7
115. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27:143-50
116. Kondoh Y, Taniguchi H, Yokoi T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005;25(3):528-33
117. Okamoto T, Ichiyasu H, Ichikado K, et al. [clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis]. Nihon Kokyuki Gakkai zasshi (The Journal of the Japanese Respiratory Society) 2006;44:359-67
118. Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993;103:1808-12
119. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003;22:821-6
120. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005;128:3310-5
121. Inase N, Sawada M, Ohtani Y, et al. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med 2003;42:565-70
122. Okamoto T, Ichiyasu H, Ichikado K, et al. Clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis. Nihon Kokyuki Gakkai Zasshi 2006;44:359-67
123. Nakamura M, Ogura T, Miyazawa N, et al. Outcome of patients with acute exacerbation of idiopathic interstitial fibrosis (ipf) treated with sivelestat and the prognostic value of serum kl-6 and surfactant protein d. Nihon Kokyuki Gakkai Zasshi 2007;45:455-9
124. Noma S, Matsuyama W, Mitsuyama H, et al. Two cases of acute exacerbation of interstitial pneumonia treated with polymyxin b-immobilized fiber column hemoperfusion treatment. Intern Med 2007;46:1447-54